▶주메뉴 바로가기
▶본문 바로가기
Korean pharmaceutical company Yuhan announced on Feb. 20 that its sales reached 1.5 trillion won (US$1.3 billion) last year, up 4 percent from the previous year. Yuhan has now become the first Korean pharmaceutical company to post annual sales exceeding 1.5 trillion won. Three other firms -- Kolma...
Koreas intravenous solution maker JW Life Science announced on Feb. 18 that it has decided to give 500 won (US$0.44) dividend per share, which amounts to around 7.91 billion won in total. Established in 1994, the firm is a subsidiary of JW Holdings which holds around 43.1 percent stake in Korea’s...
Korean drug maker Kwangdong Pharmaceutical, which has been focusing on diversifying its business portfolio, appears to be making attempts at a turnaround amid its slumping global business. The Korean company’s American dream, which started in 2015 through establishing Kwangdong USA, to sell its b...
SK Biopharmaceuticals, the new drug development subsidiary of South Korean conglomerate SK Group, announced on Feb. 14 that it had signed a deal worth US$530 million with Swiss drug company Arvelle Therapeutics to commercialize its drug candidate Cenobamate in Europe. Cenobamate is the Korean comp...
CJ Healthcare announced on Feb. 13 that it has signed a deal worth US$84 million with Mexico-based Laboratorios Carnot to exclusively supply its drug Tegoprazan for the next 10 years. Tegoprazan, which is a treatment for gastroesophageal reflux disease, is the first novel drug developed by CJ Heal...
Korean firms Genexine and SCM Life science announced on Feb. 13 that they have jointly acquired US biotech firm Argos Therapeutics for around 12.5 billion won (US$ 11.14 million) through an auction. Established in 1997, Argos, located in North Carolina, was listed on NASDAQ until 2018. The firm ...
Korean biotech firm Bridge Biotherapeutics is aiming to get listed on the second-tier KOSDAQ market this year, having picked KB Securities and Daishin Securities as its IPO manager, according to company sources on Feb. 13. “We have two new candidates that are undergoing clinical trials this year,...
Korean drug developer Samsung Bioepis announced Feb. 11 that it has inked a partnership with Chinese private equity firm C-Bridge Capital. “We expect C-Bridge to be a great partner for our business in China,” Samsung Bioepis CEO Ko Han-sung said in a statement. Established in 2014, C-Bridge Cap...
Shares of Daewoong Pharmaceutical have been rallying since the company announced on Jan. 1 that its botulinum toxin Nabota received marketing authorization from the US Food and Drug Administration. Korea’s leading drug maker and its US partner Evolus plan to start selling Nabota under the name Je...
New drug developer Voronoi is seeking to raise fresh funds worth 100 billion won (US$89 million) ahead of a potential initial public offering, according to news reports on Feb. 8. Established in 2015, Voronoi is currently developing treatments for lung cancer, brain cancer, Parkinson’s disease an...
Daewoong Pharmaceutical Chairman Jeon Seung-ho on Feb. 1 strongly refuted allegations by its rivals that it stole manufacturing secrets to develop botulinum toxin Nabota. The announcement came after a Bloomberg report that Allergan and partner Medytox have filed a complaint with the International ...
[THE INVESTOR] Korean drug maker KyungDong Pharmaceutical said on Feb. 1 that it has invested 1 billion won (US$894,694) in a biotech and health care related startup focused fund led by venture capital firm DAYLI Partners DAYLI Partners is a venture capital firm that has been focusing on investin...
[THE INVESTOR] Korean 3D bio-printer maker Rokit has secured 11 billion won (US$9.89 million) in funding from KB Investment, Korea Development Bank and DAYLI Partners, according to sources on Jan.31. The three investors have reportedly bought around 1.05 million won worth of redeemable convertibl...
[THE INVESTOR] Korean pharmaceutical firm Samsung Bioepis saw its accumulated sales in the European market hit US$545.2 million last year, data showed on Jan. 30. Sales of three biosimilar products -- Benepali, Flixabi and Imradli -- surged 44 percent on-year in 2018, according to the data pro...
[THE INVESTOR] Genosco, a US-based subsidiary of Korean bio company Oscotec, is gearing up to go public, according to industry sources on Jan. 28. The company recently sent out a request for proposals to several major securities firms, including NH Investment & Securities and Samsung Securities. ...
KB chief stresses role of finance in net-zero transition
Hyundai to produce Ioniq 5 with Indonesia’s batik design
[Bio USA] Samsung Biologics hints at sales push for new plant
LS Cable & System to build Korea's largest offshore wind farm
[Contribution] Uniting for safer food: enhancing global cooperation in food safety systems
Export dependency on China wanes
Airplane's exit door should not be difficult to open: survey
Ex-BMW designer joins Kia as exterior styling chief